Percutaneous transluminal coronary angioplasty (PTCA) is a common angioplasty used to relieve the narrowing and obstruction of coronary arteries. Restenosis occurs 30% to 50% of patients after PTCA and has been known related to inflammation and oxidation. Hai-Fu-Rong (HFR), a traditional herbal medicine, is indicated on arthralgia, dehumidify and cure rheumatism. Previous studies showed that the extracts of HFR have antioxidant, anti-proliferative and anti-inflammatory activities. Our previous study showed that the extract of HFR suppress the vascular smooth muscle cells (VSMCs) viability and migration. Protein levels of phospho-AKT, mTOR, FAK, ERK, PDGFR-β had been reduced by extract of HFR. Thereby, the purpose of this project will explore the potential effects and mechanisms of HFR on restenosis. There are four specific aims outlined in this project to clarify the interaction and relationship between HFR and restenosis. Specific Aim 1: To identify the key extractions of HFR to inhibit VSMC proliferation and migration, to promote and protect endothelial cells (ECs) as well as to reduce inflammatory and thrombosis. Specific Aim 2: To elucidate the pharmacological mechanisms of HFR on cell proliferation, migration, inflammation and anti-thrombosis. Specific Aim 3: To compare and evaluate the attenuating effects of HFR on thrombotic side effects with the current anti-restenosis drugs. Specific Aim 4: To explore the pharmacological mechanisms of the functional metabolites of HFR in vivo. All these studies will be performed by both in vitro and in vivo assays. This project will screen the constituents of HFR with abilities to inhibit VSMCs and protect ECs. These findings will provide an insight into the development of new drugs for stent coating to reduce the restenosis incidence and bring a better life quality for patients requiring stent deposition.
|Effective start/end date||8/1/18 → 7/1/19|
- Percutaneous transluminal coronary angioplasty